TY - JOUR
T1 - Association of Anti-Rotavirus IgA Seroconversion with Growth, Environmental Enteric Dysfunction and Enteropathogens in Rural Pakistani Infants
AU - Ahmed, Sheraz
AU - Iqbal, Junaid
AU - Sadiq, Kamran
AU - Umrani, Fayaz
AU - Rizvi, Arjumand
AU - Kabir, Furqan
AU - Jamil, Zehra
AU - Syed, Sana
AU - Ehsan, Lubaina
AU - Zulqarnain, Fatima
AU - Sajid, Muhammed
AU - Hotwani, Aneeta
AU - Rahman, Najeeb
AU - Ma, Jennie Z.
AU - McNeal, Monica
AU - Ann Costa Clemens, Sue
AU - Talat Iqbal, Najeeha
AU - Moore, Sean R.
AU - Ali, Asad
N1 - Funding Information:
The study was funded by the Bill and Melinda Gates foundation (AA: OPP1138727, SRM: OPP1144149). AA and SRM also received funding from Fogarty International Center (D43TW007585). Additionally, SRM received funding from Pendleton Laboratory Endowment funds. The funding sources had no role in the design of the study and collection, analysis, and interpretation of data and in writing this manuscript.
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/5/31
Y1 - 2022/5/31
N2 - Background: The underperformance of oral vaccines in children of low- and middle-income countries is partly attributable to underlying environmental enteric dysfunction (EED). Methodology: We conducted a longitudinal, community-based study to evaluate the association of oral rotavirus vaccine (Rotarix®) seroconversion with growth anthropometrics, EED biomarkers and intestinal enteropathogens in Pakistani infants. Children were enrolled between three to six months of their age based on their nutritional status. We measured serum anti-rotavirus immunoglobulin A (IgA) at enrollment and nine months of age with EED biomarkers and intestinal enteropathogens. Results: A total of 391 infants received two doses of rotavirus (RV) vaccine. 331/391 provided paired blood samples. Of these 331 children, 45% seroconverted at 9 months of age, 35% did not seroconvert and 20% were seropositive at baseline. Non-seroconverted children were more likely to be stunted, wasted and underweight at enrollment. In univariate analysis, insulin-like growth factor (IGF) concentration at 6 months were higher in seroconverters, median (25th, 75th percentile): 26.3 (16.5, 43.5) ng/ml vs. 22.5 (13.6, 36.3) ng/ml for non-seroconverters, p-value = 0.024. At nine months, fecal myeloperoxidase (MPO) concentrations were significantly lower in seroconverters, 3050(1250, 7587) ng/ml vs. 4623.3 (2189, 11650) ng/ml in non-seroconverted children, p-value = 0.017. In multivariable logistic regression analysis, alpha-1 acid glycoprotein (AGP) and IGF-1 concentrations were positively associated with seroconversion at six months. The presence of sapovirus and rotavirus in fecal samples at the time of rotavirus administration, was associated with non-seroconversion and seroconversion, respectively. Conclusion: We detected high baseline RV seropositivity and impaired RV vaccine immunogenicity in this high-risk group of children. Healthy growth, serum IGF-1 and AGP, and fecal shedding of rotavirus were positively associated with RV IgA seroconversion following immunization, whereas the presence of sapovirus was more common in non-seroconverters. Trial registration: Clinical Trials ID: NCT03588013.
AB - Background: The underperformance of oral vaccines in children of low- and middle-income countries is partly attributable to underlying environmental enteric dysfunction (EED). Methodology: We conducted a longitudinal, community-based study to evaluate the association of oral rotavirus vaccine (Rotarix®) seroconversion with growth anthropometrics, EED biomarkers and intestinal enteropathogens in Pakistani infants. Children were enrolled between three to six months of their age based on their nutritional status. We measured serum anti-rotavirus immunoglobulin A (IgA) at enrollment and nine months of age with EED biomarkers and intestinal enteropathogens. Results: A total of 391 infants received two doses of rotavirus (RV) vaccine. 331/391 provided paired blood samples. Of these 331 children, 45% seroconverted at 9 months of age, 35% did not seroconvert and 20% were seropositive at baseline. Non-seroconverted children were more likely to be stunted, wasted and underweight at enrollment. In univariate analysis, insulin-like growth factor (IGF) concentration at 6 months were higher in seroconverters, median (25th, 75th percentile): 26.3 (16.5, 43.5) ng/ml vs. 22.5 (13.6, 36.3) ng/ml for non-seroconverters, p-value = 0.024. At nine months, fecal myeloperoxidase (MPO) concentrations were significantly lower in seroconverters, 3050(1250, 7587) ng/ml vs. 4623.3 (2189, 11650) ng/ml in non-seroconverted children, p-value = 0.017. In multivariable logistic regression analysis, alpha-1 acid glycoprotein (AGP) and IGF-1 concentrations were positively associated with seroconversion at six months. The presence of sapovirus and rotavirus in fecal samples at the time of rotavirus administration, was associated with non-seroconversion and seroconversion, respectively. Conclusion: We detected high baseline RV seropositivity and impaired RV vaccine immunogenicity in this high-risk group of children. Healthy growth, serum IGF-1 and AGP, and fecal shedding of rotavirus were positively associated with RV IgA seroconversion following immunization, whereas the presence of sapovirus was more common in non-seroconverters. Trial registration: Clinical Trials ID: NCT03588013.
KW - Biomarkers
KW - Environmental enteric dysfunction
KW - Infants
KW - Malnutrition
KW - Oral vaccines
KW - Rotavirus vaccine
KW - Stunting
UR - http://www.scopus.com/inward/record.url?scp=85129973084&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2022.04.032
DO - 10.1016/j.vaccine.2022.04.032
M3 - Article
C2 - 35534310
AN - SCOPUS:85129973084
SN - 0264-410X
VL - 40
SP - 3444
EP - 3451
JO - Vaccine
JF - Vaccine
IS - 25
ER -